Abstract
The identification of the full target spectrum of active molecules, known as target deconvolution, has become an indispensable step during the drug discovery process. It is now achievable thanks to mass spectrometry–based technologies. Here we discuss these approaches in the context of epigenetic drug discovery.
Original language | English |
---|---|
Pages (from-to) | 854-857 |
Number of pages | 4 |
Journal | Nature Structural and Molecular Biology |
Volume | 26 |
Issue number | 10 |
DOIs | |
Publication status | Published - Oct 1 2019 |
ASJC Scopus subject areas
- Structural Biology
- Molecular Biology